Overview

Financials

News Ideas Discussions Technicals Forecast Seasonals Options

BDSX fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Key facts

‪123.54 M‬USD

—

−0.35USD

2005

273

Scott Hutton

biodesix.com

About

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Louisville, CO.

Ownership

‪‪145.98 M‬‬

Free Float shares

‪‪74.00 M‬‬ (50.69%)

Closely held shares

‪‪71.98 M‬‬ (49.31%)

Free Float shares

‪‪74.00 M‬‬ (50.69%)

Closely held shares

‪‪71.98 M‬‬ (49.31%)

Capital structure

Market cap

‪‪123.54 M‬‬

Debt

‪‪61.98 M‬‬

Cash & equivalents

‪‪26.34 M‬‬

Enterprise value

‪‪159.17 M‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary

‪‪123.54 M‬‬

Price to earning ratio (P/E)

—

Price to sales ratio (P/S)

1.68x

Market Cap

Net income

Revenue

Price to earning ratio (P/E)

—

Price to sales ratio (P/S)

1.68x

Valuation ratios

Q4 '23

Q1 '24

Q2 '24

Q3 '24

Q4 '24

‪0.00‬

‪1.00‬

‪2.00‬

‪3.00‬

‪4.00‬

P/S

Growth and Profitability

Company’s recent performance and margins

Performance

‪−100%‬

‪−85%‬

‪−70%‬

‪−55%‬

‪−40%‬

Q4 '23

Q1 '24

Q2 '24

Q3 '24

Q4 '24

‪‪−22.00 M‬‬

‪‪−11.00 M‬‬

‪0.00‬

‪‪11.00 M‬‬

‪‪22.00 M‬‬

Revenue

Net income

Net margin %

Revenue to profit conversion

Revenue

COGS

Gross profit

Op expenses

Op income

Non-Op income/ expenses

Taxes & Other

Net income

‪‪−9.00 M‬‬

‪0.00‬

‪‪9.00 M‬‬

‪‪18.00 M‬‬

‪‪27.00 M‬‬

Revenue

COGS

Gross profit

Expenses & adjustments

Net income

‪‪−9.00 M‬‬

‪0.00‬

‪‪9.00 M‬‬

‪‪18.00 M‬‬

‪‪27.00 M‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business

Period: 2024

Lung Diagnostic Testing

Development Services

By country

Period: 2024

United States

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue

Q1 '24

Q2 '24

Q3 '24

Q4 '24

Q1 '25

‪0.00‬

‪‪6.00 M‬‬

‪‪12.00 M‬‬

‪‪18.00 M‬‬

‪‪24.00 M‬‬

Actual

Estimate

Earnings

Next:May 7, 2025

Q1 '24

Q2 '24

Q3 '24

Q4 '24

Q1 '25

‪−0.16‬

‪−0.12‬

‪−0.08‬

‪−0.04‬

‪0.00‬

Actual

Estimate

Dividends

Dividend yield, history and sustainability

BDSX does not pay dividends

The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company

Debt level and coverage

Q4 '23

Q1 '24

Q2 '24

Q3 '24

Q4 '24

‪‪−21.00 M‬‬

‪0.00‬

‪‪21.00 M‬‬

‪‪42.00 M‬‬

‪‪63.00 M‬‬

Debt

Free cash flow

Cash & equivalents

Financial position analysis

Short term

Long term

‪0.00‬

‪‪16.00 M‬‬

‪‪32.00 M‬‬

‪‪48.00 M‬‬

‪‪64.00 M‬‬

Assets

Liabilities